Charles River Laboratories and Magellan Stem Cells announced a collaboration on Oct. 13, 2026, bringing cGMP next-generation sequencing viral safety testing to Zelestrocel, Magellan’s off-the-shelf osteoarthritis stem cell therapy candidate.
ohnson & Johnson Q3 2026 Results: sales rose 5.9% to $25.4B, adjusted EPS hit $2.59 and 2026 guidance rose to $11.10 adjusted EPS at the midpoint.
IQVIA and Veeva Systems have expanded their partnership. IQVIA Veeva clinical operations now includes Veeva CTMS, eTMF, Study Startup and Site Connect as enterprise standard applications across IQVIA clinical development studies, extending the earlier EDC partnership.
IQVIA Life Science Models were introduced at TechIQ 2026 to help life sciences companies predict clinical trial outcomes. IQVIA reports that 85% of predictions across 50 trials and 270 endpoints were on target or clinically close.
Eli Lilly has committed an additional $4.5 billion across two manufacturing sites in Lebanon, Indiana, taking its total Indiana capital expansion commitments since 2020 to more than $21 billion. The investment also marks the opening of Lilly Lebanon Advanced Therapies, the company’s first dedicated genetic medicine manufacturing facility.
Charles River Laboratories (NYSE: CRL) has introduced rapid cell banking programs that the company says cut cell bank production timelines by 40% against a 20-week industry standard. The offering pairs rapid microbiological and mycoplasma tests with NGS characterization through its iDTECT platform.
The Sanofi Regeneron Alliance Expansion adds four long-acting, Regeneron-invented immunology antibodies to the Dupixent partnership. Regeneron receives $1 billion upfront, with up to $7 billion more in potential milestones and a 50:50 profit split.
AbbVie (NYSE: ABBV) has entered a new collaboration with life sciences AI platform Valkai to apply purpose-built AI across targeted areas of clinical research, aiming to generate insights faster and support shorter development timelines.
Novo Nordisk HRS-1596 is the focus of a new exclusive license with Hengrui Pharma worth up to $2.6 billion, including $300 million upfront. The phase 1-ready GLP-1/GIP dual agonist has potential for once-weekly oral dosing.
Merck has entered into an exclusive global licensing agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor, in a transaction valued at up to $2.13 billion, including a $400 million upfront payment.
